You are here: Industry Insights > AGE1.CR.pIX

News List

Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX Production Platform PharmaSources
May 05, 2023
May 04, 2023，ProBioGen announces that their proprietary vaccine production cell line AGE1.CR.pIX has been successfully used to manufacture a viral vector product that has advanced into a randomized phase II clinical trial.
Imvaq Therapeutics Signs a Service and Commercial Product License to Use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform B3Cnewswire
January 07, 2022
ProBioGen AG is delighted to announce the execution of a service and commercial product license agreement with Imvaq Therapeutics, a biotech company developing innovative cancer immunotherapies.
Nobelpharma Signs License Agreement to Use ProBioGen’s Vaccine Production Platform contractpharma
August 13, 2021
The cell-based system for vaccine production offers a cost-effective, efficient and flexible alternative to traditional vaccine production.
Nobelpharma Signs a License Agreement for ProBioGen’s Vaccine Manufacturing Platform AGE1.CR.pIX® b3cnewswire
August 13, 2021
ProBioGen is pleased to announce that Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIXvaccine production platform to develop their lead vaccine.
ProBioGen, Nobelpharma Enter Mfg. Agreement for Vax Project contractpharma
March 25, 2021
ProBioGen AG signed a service agreement for Nobelpharma’s vaccine project leveraging ProBioGen’s vaccine development platform consisting of its AGE1.CR.pIX suspension cell line and its high performance cell culture medium, for the propagation of ...